In vitro bactericidal and anticancer activity of new metabolite, ARK42, isolated from Aspergillus repens K42

Je Won Park; Beom Seok Song; Dojin Ryu; Chan Lee; Young Bae Kim

In vitro bactericidal and anticancer activity of new metabolite, ARK42, isolated from Aspergillus repens K42

Je Won Park, Beom Seok Song, Dojin Ryu, Chan Lee, Young Bae Kim

Research output: Contribution to journal › Article › peer-review

Abstract

A novel antibacteria metabolite, ARK42, was isolated from a xerophilic fungal strain K42, and identified as Aspergillus repens based on its morphological characteristics. The metabolite exhibited antibacterial activities towards Staphylococcus aureus, Bacillus cereus, and Pseudomonas aeruginosa, with MICs of 25, 12.5, and 3.125 μg/ml, respectively, and killed Pseudomonas aeruginosa with minimal bactericidal concentration (MBC) of 12.5 μg/ml. Furthermore, anticancer activities were demonstrated against human colon cancer DLD-1 and lung cancer LXFL529 cells with an IC₅₀ of 10 and 1 μg/ml, respectively.

Original language	English
Pages (from-to)	1017-1021
Number of pages	5
Journal	Journal of microbiology and biotechnology
Volume	12
Issue number	6
Publication status	Published - 2002 Dec

Keywords

Anticancer activity
Aspergillus repens
Bactericidal activity

ASJC Scopus subject areas

Biotechnology
Applied Microbiology and Biotechnology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{0ea798bb1e834daba56161f27b40de33,

title = "In vitro bactericidal and anticancer activity of new metabolite, ARK42, isolated from Aspergillus repens K42",

abstract = "A novel antibacteria metabolite, ARK42, was isolated from a xerophilic fungal strain K42, and identified as Aspergillus repens based on its morphological characteristics. The metabolite exhibited antibacterial activities towards Staphylococcus aureus, Bacillus cereus, and Pseudomonas aeruginosa, with MICs of 25, 12.5, and 3.125 μg/ml, respectively, and killed Pseudomonas aeruginosa with minimal bactericidal concentration (MBC) of 12.5 μg/ml. Furthermore, anticancer activities were demonstrated against human colon cancer DLD-1 and lung cancer LXFL529 cells with an IC50 of 10 and 1 μg/ml, respectively.",

keywords = "Anticancer activity, Aspergillus repens, Bactericidal activity",

author = "Park, {Je Won} and Song, {Beom Seok} and Dojin Ryu and Chan Lee and Kim, {Young Bae}",

year = "2002",

month = dec,

language = "English",

volume = "12",

pages = "1017--1021",

journal = "Journal of microbiology and biotechnology",

issn = "1017-7825",

publisher = "Korean Society for Microbiolog and Biotechnology",

number = "6",

}

TY - JOUR

T1 - In vitro bactericidal and anticancer activity of new metabolite, ARK42, isolated from Aspergillus repens K42

AU - Park, Je Won

AU - Song, Beom Seok

AU - Ryu, Dojin

AU - Lee, Chan

AU - Kim, Young Bae

PY - 2002/12

Y1 - 2002/12

N2 - A novel antibacteria metabolite, ARK42, was isolated from a xerophilic fungal strain K42, and identified as Aspergillus repens based on its morphological characteristics. The metabolite exhibited antibacterial activities towards Staphylococcus aureus, Bacillus cereus, and Pseudomonas aeruginosa, with MICs of 25, 12.5, and 3.125 μg/ml, respectively, and killed Pseudomonas aeruginosa with minimal bactericidal concentration (MBC) of 12.5 μg/ml. Furthermore, anticancer activities were demonstrated against human colon cancer DLD-1 and lung cancer LXFL529 cells with an IC50 of 10 and 1 μg/ml, respectively.

AB - A novel antibacteria metabolite, ARK42, was isolated from a xerophilic fungal strain K42, and identified as Aspergillus repens based on its morphological characteristics. The metabolite exhibited antibacterial activities towards Staphylococcus aureus, Bacillus cereus, and Pseudomonas aeruginosa, with MICs of 25, 12.5, and 3.125 μg/ml, respectively, and killed Pseudomonas aeruginosa with minimal bactericidal concentration (MBC) of 12.5 μg/ml. Furthermore, anticancer activities were demonstrated against human colon cancer DLD-1 and lung cancer LXFL529 cells with an IC50 of 10 and 1 μg/ml, respectively.

KW - Anticancer activity

KW - Aspergillus repens

KW - Bactericidal activity

UR - http://www.scopus.com/inward/record.url?scp=0037001090&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0037001090

SN - 1017-7825

VL - 12

SP - 1017

EP - 1021

JO - Journal of microbiology and biotechnology

JF - Journal of microbiology and biotechnology

IS - 6

ER -

In vitro bactericidal and anticancer activity of new metabolite, ARK42, isolated from Aspergillus repens K42

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this